Amplifier
Summary
We believe our compound could transform the lives of patients, with potential in treating cardiometabolic and aging-related diseases.In 2023, Amplifier Therapeutics became the third of Cambrians pipeline companies to emerge from stealth mode. This trial will enable a wide-reaching indication strategy by informing us of the best avenues to pursue in order to maximize the impact of ATX-304 to chronic diseases affecting large populations and not adequately addressed by existing therapies.Simultaneously, RA Capital Management, a multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, and Future Ventures, a venture capital firm focused on trailblazing technology companies, have joined the Amplifier Series A financing led by Cambrian. To learn more about RA Capital Management and Future Ventures, and explore their extensive portfolio in the fields of human health and technology, please visit their respective websites: https://www.racap.com and https://future.ventures.ATX-304 is a peripherally acting pan-AMPK activator with beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of metabolic disorders, as well as cardiovascular function and exercise endurance.Amplifier TX AB, doing business as Amplifier Therapeutics, is a Sweden-based biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. For more information, please visit www.Amplifier-Tx.com.Cambrian Bio is a clinical-stage drug development company focused on creating therapeutics targeting key biological pathways that decline or malfunction with age. This model allows Cambrian to develop new drugs efficiently with highly qualified individuals, partner flexibly across the healthcare ecosystem, and return rewards to the scientists whose vision and drive build new medicines.